Drug Research
GSKs Bexsero achieves primary and secondary endpoints with reduced 3-dose schedule in safety and immunogenicity study in infants and children
GSK presented new data for its meningococcal group B vaccine, Bexsero®,1 comparing safety and immunogenicity with different dosing schedules in infants and young...
Press Releases
Pfizer reports Results From Two Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Studies At The European Society For Paediatric Infectious Diseases Meeting
Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains...
Press Releases
Pfizer Announces Results From Two Phase 3 TRUMENBA Studies At The European Society For Paediatric Infectious Diseases Meeting
Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB) strains...
Press Releases
AbbVie Inc to participate at the UBS Global Health Care Conference
AbbVie will participate in the UBS Global Healthcare Conference on Monday, May 23, 2016. Bill Chase, executive vice president and chief financial officer, will...
News
Takeda Appoints New Chief Financial Officer, James Kehoe
Takeda Pharmaceutical Company Limited announced the appointment of James Kehoe as Takeda’s new Chief Financial Officer and Corporate Officer, effective on June 15, 2016....
Industry Reports
Stada Arzneimittel AG announces First quarter of 2016 and result shows key earnings figures substantially higher than previous year
Group sales rise by 2 percent – adjusted by +4 percent Adjusted EBITDA declines slightly by 1 percent Adjusted net income increases by...
Press Releases
Mylan Launches Generic Frova Tablets for for migraine headaches in adults.
Mylan N.V. announced the U.S. launch of Frovatriptan Succinate Tablets 2.5 mg, a generic version of Endo's Frova® Tablets. Mylan received final approval from...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read